Omer Gendelman

Dr. Omer Gendelman


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Naim MahroumNaim Mahroum
Naim Mahroum
Abdulla WatadAbdulla Watad
Abdulla Watad
CBCharlie Bridgewood
Charlie Bridgewood
MMMuhammad Mansour
Muhammad Mansour
ANAhmad Nasr
Ahmad Nasr
DMDennis McGonagle
Dennis McGonagle
Background. Tocilizumab is an anti-IL-6 therapy widely adopted in the management of the so-called “cytokine storm” related to SARS-CoV-2 virus infection, but its effectiveness, use in relation to concomitant corticosteroid therapy and safety were unproven despite widespread use in numerous studies, mostly open label at the start of the pandemic. Methods: We performed a systematic review and meta-analysis of case-control studies utilising tocilizumab in COVID-19 on different databases (PubMed/MEDLINE/Scopus) and preprint servers (medRxiv and SSRN) from inception until 20 July 2020 (PROSPERO CRD42020195690). Subgroup analyses and meta-regressions were performed. The impact of tocilizumab and concomitant corticosteroid therapy or tocilizumab alone versus standard of care (SOC) on the death rate, need for mechanical ventilation, ICU admission and bacterial infections were assessed. Results. Thirty-nine studies with 15,531 patients (3657 cases versus 11,874 controls) were identified. Unadjusted estimates (n = 28) failed to demonstrate a protective effect of tocilizumab on survival (OR 0.74 ([95%CI 0.55–1.01], p = 0.057), mechanical ventilation prevention (OR 2.21 [95%CI 0.53–9.23], p = 0.277) or prevention of ICU admission (OR 3.79 [95%CI 0.38–37.34], p = 0.254). Considering studies with adjusted, estimated, tocilizumab use was associated with mortality rate reduction (HR 0.50 ([95%CI 0.38–0.64], p < 0.001) and prevention of ICU admission (OR 0.16 ([95%CI 0.06–0.43], p < 0.001). Tocilizumab with concomitant steroid use versus SOC was protective with an OR of 0.49 ([95%CI 0.36–0.65], p < 0.05) as was tocilizumab alone versus SOC with an OR of 0.59 ([95%CI 0.34–1.00], p < 0.001). Risk of infection increased (2.36 [95%CI 1.001–5.54], p = 0.050; based on unadjusted estimates). Conclusion: Despite the heterogeneity of included studies and large number of preprint articles, our findings from the first eight of the pandemic in over 15,000 COVID-19 cases suggested an incremental efficacy of tocilizumab in severe COVID-19 that were confirmed by subsequent meta-analyses of large randomized trials of tocilizumab. This suggests that analysis of case-control studies and pre-print server data in the early stages of a pandemic appeared robust for supporting incremental benefits and lack of major therapeutic toxicity of tocilizumab for severe COVID-19.

7 January 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
OGOmer Gendelman
Omer Gendelman
RSRaz Shapira
Raz Shapira
STShmuel Tiosano
Shmuel Tiosano
EPElon Pras
Elon Pras
DCDoron Comaneshter
Doron Comaneshter
HAHoward AMITAL
Howard AMITAL
Aims of the study Familial Mediterranean fever (FMF) is a hereditary, auto‐inflammatory disease, characterised by recurrent, self‐limiting attacks of fever with inflammation of the serosal membranes, joints, and skin. Chronic inflammation was previously associated with increased risk for ischaemic heart disease (IHD). However, the association between FMF and IHD remains unclear. The objective of this study is to determine whether this association exists. Methods Utilising the database of the largest health‐care provider in Israel, a cross‐sectional study was performed. The incidence of IHD was compared between patients diagnosed with FMF and age and sex‐matched controls. Chi‐square and t‐test were used for categorial and continuous variables, and cox logistics regression model was used for multivariate analysis. Survival analysis was made using Kaplan‐Meier plots and log‐rank test. Results The study included 7670 patients diagnosed with FMF and an equal number of controls without FMF. In a univariate analysis FMF was found to be associated with higher prevalence of IHD (OR 1.33) and increased mortality (OR 1.29). In a multivariate analysis FMF was found to be independently associated with increased risk for IHD (OR 1.44). Conclusion The study shows that FMF is associated with both increased risk for IHD and higher mortality rates. An early diagnosis and treatment of this disease can potentially improve patients’ life expectancy and decrease cardiac comorbidities.

12 August 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
OGOmer Gendelman
Omer Gendelman
RSRaz Shapira
Raz Shapira
STShmuel Tiosano
Shmuel Tiosano
YKYuval Kuntzman
Yuval Kuntzman
ATAvishai M. Tsur
Avishai M. Tsur
HAHoward AMITAL
Howard AMITAL
Aim To investigate the health care utilisation and drug consumption of patients with fibromyalgia (FM). Materials and Methods This is a cross-sectional study using the Clalit Health Care database. Clalit is the largest HMO in Israel, serving more than 4.4 million enrollees. We identified FM patients and age and sex-matched controls. Indicators of healthcare utilisation and drug consumption were extracted and analysed for both groups. Results The study included 14 296 FM patients and 71 324 controls. The mean age was 56 years, with a women predominance of 92%. The mean number of visits across of all healthcare services (hospitalisations, emergency department visit, general practitioner clinic visits, rheumatology clinic visits, and pain clinic visits) and the mean difference (MD) were significantly higher for FM patients compared with controls (MD 0.66, P < .001; MD 0.23, P < .001; MD 7.49, P < .001; MD 0.31, P < .001; MD 0.13, P < .001), respectively. Drug use was significantly and consistently higher among FM patients compared with controls; NSAIDs (non-steroidal anti-inflammatory drugs) OR 2.56, P < .001; Opioids OR 4.23, P < .001; TCA (tricyclic antidepressants) OR 8.21, P < .001; Gabapentinoids OR 6.31, P < .001; SSRI (selective serotonin reuptake inhibitors) OR 2.07, P < .001; SNRI (serotonin-norepinephrine reuptake inhibitor) OR 7.43, P < .001. Conclusion Healthcare utilisation and drug use are substantially higher among patients with FM compared with controls.

20 May 2021 in Ocular Immunology and Inflammation
Verified
Journal Article
Closed access
OGOmer Gendelman
Omer Gendelman
LSLiana Tripto - Shkolnik
Liana Tripto - Shkolnik
IVIris Vered
Iris Vered
MLMerav Lidar
Merav Lidar
Objective: To describe the clinical features of patients with bisphosphonate related ocular side effects (BROSE). Methods: The medical records of all patients with BROSE between January 2009 and December 2019 were reviewed. Results: Nine cases with BROSE were identified. All subjects were female. Median age at diagnosis was of 69 years. The leading indication for bisphosphonate treatment was osteoporosis (n=7), Paget’s disease of bone (n=1) and breast cancer (n=1). Six (66.67%) patients presented with uveitis, one (11%) episcleritis and two (22%) with orbital inflammation. Five events (55.5%) occurred within 10 days of initiating the bisphosphonate and the rest (44.44%) developed within 2 weeks to 3 years later. Four (44.44%) patients had concurrent thyroid disease. An association was found between underlying thyroid disease or autoimmunity. Conclusion: BROSE is an uncommon complication of bisphosphonate therapy occurring more frequently in patients with an autoimmune predisposition.

14 October 2022 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
OGOmer Gendelman
Omer Gendelman
AFAriel J Feifel
Ariel J Feifel
ATAvishai M Tsur
Avishai M Tsur
DCDoron Comanhester
Doron Comanhester
ACArnon D Cohen
Arnon D Cohen
HAHoward AMITAL
Howard AMITAL

17 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ESEinat Savin
Einat Savin
NBNiv Ben-Shabat
Niv Ben-Shabat
ALAsaf Levartovsky
Asaf Levartovsky
Adi LahatAdi Lahat
Adi Lahat
MOMahmud Omar
Mahmud Omar
KSKassem Sharif
Kassem Sharif
Background: The link between ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) is well-established, with concurrent prevalence estimates ranging from 5–10%. However, there are still significant gaps in our understanding, and a comprehensive treatment guideline for these co-diagnosed patients has yet to be established. Our objective was to explore patterns of treatment alterations following the diagnosis of AS in patients previously diagnosed with IBD, and vice versa. Additionally, we sought to determine how these modifications influence clinical outcomes in both conditions. Methods: This retrospective data-based cohort study included patients with coexisting IBD and AS that were diagnosed between the years 2009–2022 and were followed by the gastroenterology and the rheumatology units of the Sheba Medical Center, Israel. The data were extracted from the electronic health record and included demographic information, medication history, treatment modification at the time of second diagnosis, and the characteristics and activity of both IBD and AS at the index time and at the 3-month mark. Results: The study included a total of 68 patients, with a male predominance (40 patients, 59%). The median age was 43 years (IQR 31–55) and 78% had Crohn’s disease (CD). The median duration between the diagnosis of the first disease to the second one was 4 years (IQR 1–9.5). A significant proportion of patients (85%) underwent treatment modification at their second diagnosis. Out of the total cohort, 28% initiated biological therapy, 17.6% switched their biologic regimen, and 16.2% discontinued NSAIDS. Patients who underwent biologic modifications at time of the second diagnosis (the initiation/switch/augmentation of a concurrent regimen) experienced significantly higher rates of clinical improvement in either IBD or AS at the 90-day follow-up compared to patients who did not (68% vs. 32%, p = 0.004), and biologic modification was found to be an independent predictor for clinical improvement (OR 3.69, CI 1.08–12.58, p = 0.037). Conclusions: Our findings suggest that biologic therapy modification at the time of the second diagnosis was associated with a higher rate of improvement in AS/IBD at the 90-day follow-up.